Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

dogood Apr. 7 at 10:26 PM

$SILO look at $QNCX half a billion volume

0 · Reply

hailmaryfullofgrace Apr. 7 at 10:26 PM

$QNCX insane Volume today. it's shorted like crazy. Merger news likely imminent.

0 · Reply

The_Assassin Apr. 7 at 10:24 PM

$AIXI $HCAI $QNCX $UCAR $CUPR

1 · Reply

Bossbaby14 Apr. 7 at 10:24 PM

$QNCX I'd love to see this bounce above .30 tonight for a strong rally into tomorrow

1 · Reply

Suza271 Apr. 7 at 10:24 PM

$QNCX I'm pretty sure he was talking about his AI scanner.

1 · Reply

The_Assassin Apr. 7 at 10:23 PM

$AIXI $HCAI $QNCX $UCAR $CUPR you need to ask what I meant by AI , it means simply i use my AI Scanner to find these stocks smh.

0 · Reply

HarmonyPioneer67 Apr. 7 at 10:21 PM

$QNCX

1 · Reply

Kesiya Apr. 7 at 10:20 PM

🎯💎#3 Stocks with High Potential for Upward Movement During/Overnight-Premarket🚀⚡📊 #1.$LNKS Float :1.33M #2.$UCAR Float :2.1M #3.$QNCX Float47.75M #4.$JEM Float :20.41M #5.$GNLN Float :3.75M

0 · Reply

Kesiya Apr. 7 at 10:20 PM

$QNCX Float47.75M Buy zone!

0 · Reply

22Allin Apr. 7 at 10:18 PM

$GRML $QNCX this could go more is a debt free already

0 · Reply

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Feb 12, 2026, 12:27 PM EST - 7 weeks ago

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Feb 10, 2026, 3:05 PM EST - 2 months ago

Quince Therapeutics Stock Explodes 300% On Strategic Review

Feb 9, 2026, 4:05 PM EST - 2 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 2 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 2 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 4 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 4 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Nov 24, 2025, 8:00 AM EST - 4 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 5 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 5 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Sep 25, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 11, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 9 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 10 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 11 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

dogood Apr. 7 at 10:26 PM

$SILO look at $QNCX half a billion volume

0 · Reply

hailmaryfullofgrace Apr. 7 at 10:26 PM

$QNCX insane Volume today. it's shorted like crazy. Merger news likely imminent.

0 · Reply

The_Assassin Apr. 7 at 10:24 PM

$AIXI $HCAI $QNCX $UCAR $CUPR

1 · Reply

Bossbaby14 Apr. 7 at 10:24 PM

$QNCX I'd love to see this bounce above .30 tonight for a strong rally into tomorrow

1 · Reply

Suza271 Apr. 7 at 10:24 PM

$QNCX I'm pretty sure he was talking about his AI scanner.

1 · Reply

The_Assassin Apr. 7 at 10:23 PM

$AIXI $HCAI $QNCX $UCAR $CUPR you need to ask what I meant by AI , it means simply i use my AI Scanner to find these stocks smh.

0 · Reply

HarmonyPioneer67 Apr. 7 at 10:21 PM

$QNCX

1 · Reply

Kesiya Apr. 7 at 10:20 PM

0 · Reply

Kesiya Apr. 7 at 10:20 PM

$QNCX Float47.75M Buy zone!

0 · Reply

22Allin Apr. 7 at 10:18 PM

$GRML $QNCX this could go more is a debt free already

0 · Reply

trinidadjamezz Apr. 7 at 10:18 PM

$QNCX short it more let me load up some more clowns

1 · Reply

HarmonyPioneer67 Apr. 7 at 10:18 PM

$QNCX Our AIDE technology platform reflects more than 20 years of innovation and approximately $100 million of investment, which has resulted in innovation that creates high barriers to competitive entry.

0 · Reply

HarmonyPioneer67 Apr. 7 at 10:18 PM

$QNCX a few weeks ago the website was locked down now it’s open and updated https://quincetx.com/team/

1 · Reply

Wardog17 Apr. 7 at 10:17 PM

$QNCX

1 · Reply

trinidadjamezz Apr. 7 at 10:15 PM

$QNCX

0 · Reply

GODofPoor Apr. 7 at 10:15 PM

$ORBS ARK, BITMINE, insiders.... sounds like a cohordinated plan is preparing behind the scene. 🫳 💣 $AIXI $SRXH $QNCX $BEAT

1 · Reply

TCLutz Apr. 7 at 10:14 PM

$AIXI $CUPR $HCAI $QNCX $UCAR Make it stop! Lmao! 🛑 Qncx is a reverse merger play. Has nothing to do with AI.

1 · Reply

Bossbaby14 Apr. 7 at 10:13 PM

$QNCX something wants to give.. Which way is the question… ⬆️

0 · Reply

FillSniper42 Apr. 7 at 10:13 PM

$CYCU will be the top gainer this week, mark this post. $UCAR $QNCX $SKIL $HCAI top gainer sin AH watching for pre market tomorrow

1 · Reply

The_Assassin Apr. 7 at 10:11 PM

Revised AI List sorry folks , my AI scanner drunk $AIXI $HCAI $QNCX $UCAR $CUPR Lets go

1 · Reply

Wardog17 Apr. 7 at 10:10 PM

$QNCX you right

1 · Reply

hailmaryfullofgrace Apr. 7 at 10:09 PM

$QNCX remember $GRML went from 16 cents to 2 dollars on merger news. that's the kind of move I'm looking for here

1 · Reply

Market Cap	5.51M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	16.53

Volume	535,198,375
Avg Vol	85,247,102
Day's Range	N/A - N/A
Shares Out	55.68M
Stochastic %K	10%
Beta	1.33
Analysts	Hold
Price Target	$6.50